List view / Grid view


Filter the results



Amarantus forms Elto Pharma for CNS disorders and MANF Therapeutics for ophthalmology

18 April 2017 | By Niamh Marriott, Junior Editor

Amarantus Bioscience has formed a wholly-owned subsidiary named Elto Pharma for the purpose of creating investment vehicles focused exclusively on the further development of Eltoprazine, Amarantus' mid-stage central nervous system (CNS) symptomatic treatment for Adult Attention Deficit and Hyperactivity Disorder (Adult ADHD), Alzheimer's Aggression and Parkinson's disease Levodopa-induced Dyskinesia (PD-LID).


Santen establishes subsidiary in United Kingdom

4 November 2014 | By Santen Pharmaceutical Co

Santen Pharmaceutical Co., Ltd. announced the establishment of a wholly owned subsidiary in The United Kingdom (UK) to serve customers and patients in the UK and Ireland...